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Two recent publications in Vaccine estimated potential favor-
ble cost-effectiveness for HPV vaccination of teenage girls in
he Netherlands [1,2]. Just a few months ago, de Kok et al. con-
luded in another journal that “In theNetherlands, HPV vaccination
s not cost-effective even under favorable assumptions” [3]. I
ighly appreciate their thorough analysis of vaccinating 12-year-
ldDutch girls and their elegantmodel developed, butwould argue
hat this speciﬁc conclusion of their paper is based on inadequately
electing the analyses considered to be themost important ones. In
articular, the authors present a cost-effectiveness ratio of D53,500
erquality-adjusted life-year (QALY) gainedas their primary result,
ased on a speciﬁc set of assumptions and parameters. Notably,
iscount rates of 3% for both money and QALYs were underlying
his cost-per-QALY estimate. To provide insight on the variability
round this result, in sensitivity analysis broad ranges for assump-
ions and parameters were investigated, again using discount rates
f 3% over the whole spectrum.
Nowadays, many countries have deﬁned guidelines on the
ethodology for adequately performing cost-effectiveness anal-
sis [4]. Such guidelines are crucial for achieving consistent and
omparable economic analyses for innovative drugs, vaccines and
iagnostics that potentially enter the health-care market through
he frameworks of reimbursement within national drug systems,
accination programs and health-insurance plans. In times when
imits of health-care budgets seem to increasingly put forward
ctual constraints on reimbursement, such consistent and compa-
able analyses are eminent if one wants to validly decide what to
eimburse andwhat todeny.Also, theNetherlandshasdeﬁned such
uidelines for “good health-economic practice”, involving areas
uch as sensitivity analysis, sources for standard costing of health-
are resourceuse,methods forQALYmeasurement anddiscounting
5]. The development of these guidelines went along a careful
rocess, involving experts from medical, pharmaceutical, phar-
acoeconomic and health-economic sciences and international
onsultations [5].
The speciﬁc guideline for discounting prescribes the applica-
ion of different discount rates for money and QALYs, in particular
264-410X/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
oi:10.1016/j.vaccine.2009.10.109at 4% and 1.5%, respectively. (Notably, discounting is preformed to
correct for time preference.) These rates were derived from apply-
ing a previously validated mathematical economic model for such
differential discounting, to the speciﬁc Dutch situation [6,7]. With
most other countries prescribing similar discount rates for money
and QALYs in their guidelines rather than differential discounting,
the Dutch rates had to be strongly defended in the scientiﬁc litera-
ture [8–10]. Some key aspects in this debate referred to the lack of
comparability of cost-effectiveness analyses performed using dif-
ferential discounting with previous analyses and analyses in other
countries on the one hand, versus underlying strong arguments
of differential growth rates achieved in the overall economy and
in the health-care sector justifying differential discounting on the
other hand. Obviously, this debate has further strengthened the
credibility of differential discounting and Belgium and Luxemburg
have now taken over this Dutch discounting guideline [4]. In the
Netherlands, all new innovative drugs submitted for reimburse-
ment in recent years for the drugs reimbursement system had
to present a cost-effectiveness analysis performed conform the
guidelines, inclusive adequate discounting at the rates mentioned.
In fact, both HPV-vaccines have gone through this procedure in
attempting reimbursement for those groups outside the national
vaccination program, notably women of 17 years and older [11].
Analyses on new drugs that fail to apply the adequate discount
rates are neglected in the reimbursement decision-making process
as they come upwith incomparable results and are thus inherently
irrelevant.
With discounting at 3% for both money and QALYs, de Kok et al.
obviously do not apply the adequate discount rates, rendering – I
would argue – their primary analysis as irrelevant. In the latter sec-
tion of their paper, the authors do state that “. . . the Dutch Health
Care Insurance Board . . . recommended that costs and effects were
to be discounted at 4% and 1.5%, respectively, per year . . . apply-
ing these rates would reduce the costs for HPV vaccination . . . to
D19,700 per QALY gained”. Unfortunately, no sensitivity analysis
surrounding this value is now presented in the paper, thus lacking
to provide crucial insights on the robustness of this speciﬁc, yet
most important value. So, rather than presenting the D19,700-per-
QALYvalueas theirprimary result andperformadequate sensitivity
analysis surrounding this, deKoket al. built their analyses andargu-
ments on a cost-per-QALY estimate derived using discount rates at
3% that have never been discussed in the Netherlands, are certainly
not in the guideline and actually are irrelevant for the Dutch deci-
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ion context. Strikingly, the authors provide no rationale nor any
eference for their choice on discount rates. It is generally known
hat results on cost-effectiveness of vaccines are highly sensitive to
he exact discount percentages chosen [12,13], further strengthen-
ng the relevance of using the appropriate rates in this speciﬁc case
f HPV vaccination.
As the design of the model by de Kok et al. is compara-
le to that published by other research groups that estimated
ost-effectiveness of HPV vaccination [1,2,14], comparable cost-
ffectiveness ratios from these analyseswouldbe expected. Indeed,
f the only relevant ratio from de Kok et al. at D19,700 would be
aken, the similarity is striking. All analyses come up with cost-
ffectiveness ratios varying from D18,000 to just under D20,000 per
ALY. Cost-effectiveness ratios below or even just above D20,000
er QALY are certainly generally considered “cost-effective” in the
etherlands and justifying the implementation of the respective
edical technology under consideration [15,16]. So, several inde-
endent analyses – inclusive the one by de Kok et al. – have
ow assessed that cost-effectiveness of HPV vaccination of young
eenage girls is cost-effective. Lacking in the paper by de Kok et al.
aper, yet present in the others, sensitivity analyses proved that
his result is quite robust for varying relevant assumptions in the
odel within plausible ranges. I conclude that the conclusion by
e Kok et al. is misleading, should be re-visited and would proba-
ly better be formulated as “In the Netherlands, HPV vaccination is
ikely to be cost-effective if compared with screening alone”, and
hat is fully in line what other studies – with 2 of them in Vaccine –
ecently found [1,2,14].
unding
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